Mirum released preliminary 2025 results and they beat the upper end of their guidance. Net product sales came in around $520 million. LIVMARLI was the main driver with $359 million, up 69% year over year. They are guiding for $630 million to $650 million in sales for 2026. They also mentioned the Bluejay Therapeutics acquisition should close later this month to expand their pipeline. Looking ahead, they have Volixibat data expected in Q2 2026 and LIVMARLI expansion data in Q4. Cash balance is currently around $392 million.